News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|December 22, 2022

Depression and Comorbid Health Conditions

Author(s)Gustavo Alva, MD, DFAPA, Charles Montano, MD, Carmen Kosicek, MSN, PMHNP-BC

Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.

Episodes in this series

EP. 1 Impact of MDD Episode Duration and Recurrences

EP. 1 Impact of MDD Episode Duration and Recurrences

EP. 2 Depression and Comorbid Health Conditions

EP. 2 Depression and Comorbid Health Conditions

EP. 3 Perception of MDD in the Healthcare Community

EP. 3 Perception of MDD in the Healthcare Community

EP. 4 Monitoring Recommendations for MDD

EP. 4 Monitoring Recommendations for MDD

EP. 5 Treatment Options for MDD

EP. 5 Treatment Options for MDD

EP. 6 Treatment Approaches for Episodic and Chronic MDD

EP. 6 Treatment Approaches for Episodic and Chronic MDD

EP. 7 Current Challenges With MDD Treatment Options

EP. 7 Current Challenges With MDD Treatment Options

EP. 8 Impact of Different MDD Classes of Treatment on Time to Response

EP. 8 Impact of Different MDD Classes of Treatment on Time to Response

EP. 9 Unmet Needs in MDD Treatment Paradigm

EP. 9 Unmet Needs in MDD Treatment Paradigm

EP. 10 Key Takeaways for the Management of MDD

EP. 10 Key Takeaways for the Management of MDD

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

David Medina

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

ByDavid Medina, MD, FAPA

December 2nd 2025

Looking Back: Key Insights from November 2025

ByJessica Walters

November 28th 2025

TNX-102SL IND major depressive disorder

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

ByJessica Walters

November 24th 2025

transcranial magnetic stimulation depression treatment

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

ByRachel Rohaidy, MD

November 24th 2025

Juan Oms

Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA

ByJuan D. Oms, MD, FAPA

November 22nd 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Quantifying Generative AI Use for Mental Health Advice Among Adolescents

The Future Directions of Psychedelics: A Conversation With Guy Goodwin, MD

© 2025 MJH Life Sciences^®

All rights reserved.